Pharmstandard

Pharmstandard
Name	Pharmstandard
Native name	Фармстандарт
Type	Public
Industry	Pharmaceuticals
Founded	2003
Founder	Alexey Repik
Headquarters	Moscow, Russia
Key people	Alexey Repik
Products	Pharmaceuticals, generic drugs, OTC
Revenue	(see Financial performance)

Pharmstandard

Pharmstandard is a Russian pharmaceutical company founded in 2003, headquartered in Moscow, noted for production of generic and branded medicines distributed across Russia, the Commonwealth of Independent States, and select international markets. The company has participated in collaborations and regulatory interactions with agencies such as the Ministry of Health (Russia), engaged with capital markets including the Moscow Exchange, and faced scrutiny from institutions like the Federal Antimonopoly Service (Russia). Its activities intersect with major industry players including R-Pharm, OTC Pharma, and multinational firms such as Sanofi and Pfizer through licensing, competition, and procurement processes.

History

Pharmstandard was established in 2003 amid post-Soviet restructuring that involved entities formerly connected to institutes like the Moscow State University of Medicine and Dentistry, research centers such as the Chumakov Institute of Poliomyelitis and Viral Encephalitides, and industrial assets from regional producers in Saratov and Tomsk. Early strategic moves included acquisitions and consolidation of producers previously linked to state-owned enterprises and collaborations with international firms like Sanofi-Aventis and Actavis to expand portfolios and regulatory registrations. During the 2000s the company pursued listing activities related to the Moscow Exchange and engaged with investment banks such as VTB Capital and Goldman Sachs for financing and advisory. In the 2010s Pharmstandard expanded domestic manufacturing by acquiring facilities in regions including Ufa, Omsk, and Yaroslavl, while participating in public procurement frameworks overseen by ministries like the Ministry of Industry and Trade (Russia).

Corporate structure and ownership

The corporate structure has centered on a holding model with a parent company controlling subsidiaries focused on prescription drugs, over-the-counter (OTC) products, and contract manufacturing organizations (CMOs), interacting with corporations such as R-Pharm and state-affiliated entities like Rusnano in investment contexts. Major shareholders and key figures have included entrepreneurs and institutional investors who engaged market intermediaries such as Sberbank and asset managers like Troika Dialog. Governance has been shaped by Russian corporate law and oversight from agencies including the Central Bank of the Russian Federation for compliance and financial reporting, with board-level interactions involving independent directors drawn from sectors linked to Skolkovo Foundation initiatives and academic institutions such as Sechenov University.

Products and research

Pharmstandard's product range comprises branded generics and OTC lines spanning therapeutic areas treated in centers like Sechenov University Hospital and institutes such as the Pirogov Russian National Research Medical University. Prominent products historically included cardiovascular preparations, analgesics, and neurological treatments distributed via pharmacy chains such as A-Beta Pharmacy and wholesalers including Protek. Research and development activities were coordinated with academic partners including Russian Academy of Sciences institutes, specialized research bodies like the Gamaleya Research Institute of Epidemiology and Microbiology, and international collaborators on licensing deals with firms such as Pfizer and Novartis. Clinical trials and regulatory submissions referenced standards from organizations such as the World Health Organization and harmonization efforts with authorities like the European Medicines Agency in cross-border contexts.

Manufacturing and facilities

Manufacturing sites operated by the company were located in industrial regions including Tomsk, Saratov Oblast, and Nizhny Novgorod, featuring facilities for solid oral dosage forms, injectables, and sterile production tailored to markets served by distributors like Pharmstandard-Urals and logistics providers such as RZD Logistics. Capital investments and modernization projects drew on financing from Russian banks including VTB and multinational equipment suppliers with ties to companies like GE Healthcare and Siemens Healthineers. Quality control and accreditation referenced standards used by institutes like the Federal State Unitary Enterprise “Gosstandart” and testing partnerships with laboratories connected to Roszdravnadzor oversight.

Financial performance

Financial results reflected revenues from pharmaceutical sales, procurement contracts, and export operations monitored by analysts from firms such as Sberbank CIB and rating agencies including Moody's and Standard & Poor's in assessments of creditworthiness. The company’s listings and capital market activities involved transactions on the Moscow Exchange and engagements with institutional investors like VEB.RF-linked funds and private equity groups. Profitability fluctuated with currency movements tied to the Russian ruble, shifts in public procurement policy managed by the Ministry of Health (Russia), and competitive dynamics involving multinational manufacturers such as Teva Pharmaceutical Industries and Novartis.

Controversies and legal issues

Pharmstandard encountered controversies involving regulatory disputes with agencies such as Roszdravnadzor and competition inquiries by the Federal Antimonopoly Service (Russia), as well as legal proceedings in commercial courts in jurisdictions like Moscow Arbitration Court and arbitration involving counterparties including distributors and suppliers. High-profile issues included disputes over procurement contracts with regional health authorities in St. Petersburg and allegations raised in media outlets such as Kommersant and The Moscow Times about competitive practices and pricing strategies. Investigations and litigation involved interactions with law firms and advisors tied to entities like Baker McKenzie and domestic counsel appearing before tribunals including the Arbitrazh Court of Moscow.

Category:Pharmaceutical companies of Russia